Serum concentration of chromogranin A at admission: An early biomarker of severity in critically ill patients

Annals of Medicine

Volumn 41, Issue 1, 2009, Pages 38-44

  Zhang, Dan ^a,b,d   Lavaux, Thomas ^a,c   Sapin, Rémy ^c   Lavigne, Thierry ^a,c   Castelain, Vincent ^a,c   Aunis, Dominique ^b   Metz Boutigue, Marie Hélène ^b   Schneider, Francis ^a,c  

^a HÔPITAL DE HAUTEPIERRE   (France)

^b INSERM   (France)

^c UNIVERSITÉ DE STRASBOURG   (France)

^d CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Chromogranin A; Critically ill; Outcome; Procalcitonin; SAPS; Septic shock; Stress

Indexed keywords

C REACTIVE PROTEIN; CHROMOGRANIN A; PROCALCITONIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ADULT; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALCITONIN; CHROMOGRANIN A; CRITICAL ILLNESS; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PATIENT ADMISSION; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; ROC CURVE; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 60549095841     PISSN: 07853890     EISSN: 16512219     Source Type: Journal    
DOI: 10.1080/07853890802199791     Document Type: Article

References (20)

1. Brun-Buisson C. The epidemiology of the systemic inflammatory response. Intensive Care Med. 2000;26 Suppl 1: S64-74.
2. Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med. 2001;164: 396-402.
3. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA. 1993;270:2957-63.
4. Banks P, Helle KB. The release of proteins from the stimulated adrenal medulla. Biochem J. 1965;97:40C-1C.
5. Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. N Engl J Med. 2003;348:1134-49.
6. Aardal S, Helle KB. The vasoinhibitory activity of bovine chromogranin A fragment (vasostatin) and its independence of extracellular calcium in isolated segments of human blood vessels. Regul Pept. 1992;41:9-18.
7. Glattard E, Angelone T, Strub JM, Corti A, Aunis D, Tota B, et al. Characterization of natural vasostatin-containing peptides in rat heart. FEBS J. 2006;273:3311-21.
8. Cryer PE, Worstman J, Shah SD, Nowak RM, Deftos LJ. Plasma chromogranin A as a marker of sympathochromaffin activity in humans. Am J Physiol. 1991;260 Pt 1:E243-6.
9. Rozansky DJ, Wu H, Tang K, Parmer RJ, O'Connor DT. Glucocorticoid activation of chromogranin A gene expression. Identification and characterization of a novel glucocorticoid response element. J Clin Invest. 1994;94:2357-68.
10. Giusti M, Sidoti M, Augeri M, Rabitti C, Minuto F. Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man. Eur J Endocrinol. 2004;150:299-303.
11. Antonelli M, Levy M, Andrews PJ, Chatre J, Hudson LD, Manthous C, et al. Hemodynamic monitoring in shock and implication for management. Intensive Care Med. 2007;33:575-90.
12. Ziegler MG, Kennedy B, Morrissey E, O'Connor DT. Norepinephrine clearance, chromogranin A and dopamine beta hydroxylase in renal failure. Kidney Int. 1990;37: 1357-62.
13. Ceconi C, Ferrari R, Bachetti, Opasich C, Volterrani M, Colombo B. Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. Eur Heart J. 1990;23:967-74.
14. Estensen ME, Hognestad A, Syversen U, Squire I, Ng L, Kjekshus J, et al. Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarction. Am Heart J. 2006;152:927.e1-6.
15. Tasiemski A, Hammad H, Vandenbulcke F, Breton C, Bilfinger TJ, Pestel J, et al. Presence of chromogranin-derived antimicrobial peptides in plasma during coronary artery-bypass surgery and evidence of an immune origin of these peptides. Blood. 2002;100:553-9.
16. Lominadze G, Powell DW, Luerman GC, Link AJ, Ward RA, Mc Leisch KR. Proteomic analysis of human neutrophil granules. Mol Cell Proteomics. 2005;4:1503-21.
17. Silverman MN, Pearce BD, Biron CA, Miller AH. Immune modulation of the hypothalamic-pituitary-adrenal (HPA) axis during viral infection. Viral Immunol. 2005;18:41-71.
18. Ciesielski-Treska J, Ulrich G, Chasserot-Golaz S, Zwiller J, Revel MO, Aunis D, et al. Mechanisms underlying neuronal death induced by chromogranin A-activated microglia. J Biol Chem. 2001;276:13113-20.
19. Kingham PJ, Pocock J. Microglial apoptosis induced by chromogranin A is mediated by mitochondrial depolarisation and the permeability transition but not by cytochrome C release. J Neurochem. 2000;74:1452-62.
20. Adrie C, Bachelet M, Vayssier-Taussat M, Russo-Marie F, Bouchaert I, Adib-Conquy M, et al. Mitochondrial membrane potential and apoptosis peripheral blood monocytes in severe human sepsis. Am J Respir Crit Care Med. 2001;164:389-95.